Equity Overview
Price & Market Data
Price: $31.40
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $3,017,916,416
Daily Volume: 0
Performance Metrics
1 Week: -15.26%
1 Month: -15.13%
3 Months: 5.71%
6 Months: -25.05%
1 Year: 274.2%
YTD: -27.36%
Company Details
Employees: 196
Sector: Health technology
Industry: Biotechnology
Country:
Details
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.